The Lancet Regional Health. Europe (Aug 2024)
Factors associated with acceleration of clinical development for infectious diseases: a cross-sectional analysis of 10-year EMA registration dataResearch in context
Abstract
Summary: Background: Clinical trials feature centrally in the development of drugs and vaccines to determine safety and efficacy. Clinical development can be slow and may have a duration of more than ten years. Global public health threats such as Ebola virus disease (EVD) and COVID-19 have demonstrated that it is possible to accelerate clinical trials while maintaining safety and efficacy. We investigated acceleration in clinical trials over the past decade and identified factors associated with acceleration for drugs targeting infectious diseases. Methods: A cross-sectional study was performed of all medicinal compounds targeting infectious diseases that received marketing authorisation by the European Medicines Agency (EMA) between 2012 and 2022. We calculated median clinical development time in years between the first phase 1 trial enrolment date and the authorisation date. Multivariable linear regression analysis was performed to identify factors associated with shorter development times. Findings: Eighty-one trajectories were included. The median clinical development time was 7.3 years (IQR 4.4–12.3). The fastest times belonged to drugs and vaccines targeting COVID-19 (1.3 years, IQR 0.8–1.6), EVD (5.5 years, IQR 5.1–5.8), and Hepatitis A-E (5.5 years, IQR 3.9–8.2). Factors associated with shorter development times were outbreak setting (−5.4 years [95% CI, −8.2 to −2.6]), accelerated assessment status (−4.0 years [95% CI, −7.6 to −0.5]), and drugs with combined compounds (−2.7 years [95% CI, −4.9 to −0.4]). Interpretation: Clinical development time for infectious disease-related drugs and vaccines was relatively short, and outbreak setting and accelerated EMA assessment were associated with shorter development times. Funding: Amsterdam Public Health research institute.
